Drugs / QTX3046
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06428500 | May 2024 → Jul 2027 expected | neoplasm | Quanta Therapeutics | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2023-04-14 | Quanta Therapeutics | Results Quanta Therapeutics Presents Data from KRAS Inhibitor Pipeline at Annual AACR Meeting in Late-Breaking Research Session quantatx.com ↗
QTX3034, a multi-KRAS inhibitor, and QTX3046, a G12D-selective KRAS inhibitor, demonstrate favorable preclinical profiles, including potent anti-tumor activity with oral bioavailability and brain penetration, supporting the initiation of IND-enabling studies and clinical development for KRAS-driven solid tumor indications. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2024-06-27 | Quanta Therapeutics | Quanta Announces Dosing of First Patient in Phase 1/1b Clinical Trial of QTX3046, an Oral KRAS G12D -Selective Dual-State Allosteric Inhibitor, and Other Program Updates quantatx.com ↗ |
| 2023-04-14 | Quanta Therapeutics | Quanta Therapeutics Presents Data from KRAS Inhibitor Pipeline at Annual AACR Meeting in Late-Breaking Research Session quantatx.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | QTX3046 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06428500 ↗ |
| Route | Oral | “QTX3046 will be administered orally at escalating doses as defined in the protocol based on dose level assignment” NCT06428500 ↗ |